Mariaserena Giliberto

Title: Mariaserena Giliberto: Innovator in Cancer Treatment

Introduction

Mariaserena Giliberto is a prominent inventor based in Oslo, Norway. He has made significant contributions to the field of cancer treatment, particularly through his innovative research on ALK inhibitors. His work focuses on addressing ALK-negative cancers and plasma cell-mediated diseases, which are critical areas in oncology.

Latest Patents

Giliberto holds a patent for "ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases." This invention provides a method for treating ALK-negative/LTK-positive cancer by administering a pharmaceutically effective dose of a linear inhibitor of ALK. The invention is particularly useful in treating multiple myeloma, including cases that are resistant to proteasome inhibitors. He has 1 patent to his name.

Career Highlights

Giliberto is affiliated with the University of Oslo, where he conducts his research and development in cancer therapies. His academic background and ongoing research contribute to the advancement of medical science, particularly in the treatment of challenging cancer types.

Collaborations

Giliberto collaborates with notable colleagues, including Hesso Farhan and Ludvig Munthe. Their combined expertise enhances the research efforts at the University of Oslo, fostering innovation in cancer treatment.

Conclusion

Mariaserena Giliberto is a key figure in the development of novel cancer therapies, with a focus on ALK inhibitors. His contributions are vital in the ongoing fight against cancer, and his work continues to inspire advancements in medical research.